©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Antisense Inhibition of Basic Fibroblast Growth Factor Induces Apoptosis in Vascular Smooth Muscle Cells (*)

(Received for publication, January 18, 1996; and in revised form, March 14, 1996)

Jonathan C. Fox (§) Jason R. Shanley

From the Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Basic fibroblast growth factor (bFGF), a potent mitogen for many cell types, is expressed by vascular smooth muscle cells and plays a prominent role in the proliferative response to vascular injury. Basic FGF has also been implicated as a survival factor for a variety of quiescent or terminally differentiated cells. Autocrine mechanisms could potentially mediate both proliferation and cell survival. To probe such autocrine pathways, endogenous bFGF production was inhibited in cultured rat vascular smooth muscle cells by the expression of antisense bFGF RNA. Inhibition of endogenous bFGF production induced apoptosis in these cells independent of proliferation, and apoptosis could be prevented by exogenous bFGF but not serum or epidermal growth factor. The induction of apoptosis was associated with an inappropriate entry into S phase. These data demonstrate that interruption of autocrine bFGF signaling results in apoptosis of vascular smooth muscle cells, and that the mechanism involves disruption of normal cell cycle regulation.


INTRODUCTION

Basic fibroblast growth factor (bFGF) (^1)belongs to a multigene family with important roles in embryonic mesodermal and neuroectodermal development as well as angiogenesis and wound repair in the mature organism(1, 2) . It is a potent mitogen for many cell types, including vascular smooth muscle cells(3) . Basic FGF is found in quiescent smooth muscle cells of the arterial media(4) , and its release following vascular injury has been implicated in driving the initial proliferative response of medial smooth muscle cells, at least by a paracrine mechanism(5) . The concomitant expression of both bFGF and cell surface FGF receptors by smooth muscle cells suggests that autocrine FGF signaling has important phenotypic consequences. Autocrine FGF signaling has been reported to contribute to smooth muscle cell migration (6) and may also participate in proliferation, as has been reported for other cell types(7, 8, 9, 10) . Other consequences of autocrine FGF signaling in vascular smooth muscle cells, such as the promotion of cell survival, have not been explored.

A variety of cell types that are either terminally differentiated or normally remain in a quiescent state in the adult organism express FGF, but the autocrine functions of FGF in this context have not been elucidated. There is good experimental evidence that FGF can reside in the extracellular matrix around nondividing cells as a storage form, with its mitogenic activity available in the event of tissue damage and a requirement for repair or scar formation(11, 12, 13) . However, the widespread expression and intracellular location of FGF in nondividing cells suggests other functions, and has spurred studies of the ability of FGF to promote cell survival. The survival-promoting activity appears to be distinct from the mitogenic effects of FGF, as it has been documented in nonproliferating cells(14, 15) , including terminally differentiated cells of neuronal origin(16, 17) . How FGFs promote survival through an autocrine mechanism in this context has not been defined but may be through the prevention of apoptosis, or programmed cell death. That FGFs are autocrine survival factors has been suggested by studies in vitro(15) and in vivo(18) . The notion that exogenous FGFs promote survival by preventing apoptosis, at least through a paracrine mechanism, has been suggested by studies in PC12 cells (19) and endothelial cells(20, 21) . However, these studies do not distinguish between the survival function of FGFs and either their ability to modulate phenotype or stimulate mitogenesis.

These observations, coupled with the presence of bFGF in medial smooth muscle cells of the arterial media, prompted the hypothesis that autocrine bFGF supports smooth muscle cell proliferation, survival, or both. Vascular smooth muscle contributes to normal vessel function, the development of vascular diseases, and the response to vascular injury. There is a growing appreciation that smooth muscle cell apoptosis contributes to vascular development, physiologic adaptation, and vascular remodeling in response to the natural progression or invasive treatment of human vascular disease(22, 23, 24, 25) . The role of autocrine FGF signaling in smooth muscle cell proliferation or survival has not been clearly defined. In order to probe the autocrine function of bFGF in vascular smooth muscle cells, endogenous expression was inhibited using an antisense strategy, and the functional consequences were examined.


EXPERIMENTAL PROCEDURES

Recombinant Adenoviruses

The Ad.ASbFGF virus was constructed by replacement of the beta-galactosidase cDNA with a 1.1-kilobase rat bFGF cDNA containing the entire coding sequence plus 5`-untranslated region sequences (gift of Dr. Andrew Baird, Whittier Institute; GenBank accession number M22427) (26) in the pAd.CMVlacZ shuttle vector (gift of Dr. James Wilson, University of Pennsylvania). The resulting shuttle vector pAd.CMV.ASbFGF was cotransfected with the E1-, E3-deleted, human adenovirus serotype 5 mutant dl7001 (27) by calcium phosphate coprecipitation into human embryonal kidney 293 cells (CRL-1573, American Type Culture Collection, Bethesda MD), generating the recombinant adenovirus Ad.ASbFGF by homologous recombination(28) . Either Ad.CMVlacZ encoding bacterial beta-galactosidase (gift of Dr. James Wilson, University of Pennsylvania) (27) or Ad5/RSV/GL2 encoding firefly luciferase (gift of Dr. Brent French, Baylor School of Medicine)(29) , were used as control viruses in these and subsequent experiments.

Recombinant adenovirus was identified by PCR amplification of putative recombinant plaques using one vector-specific and one insert-specific primer. The vector-specific primer (5`-AGACATGATAAGATACAT-3`) corresponds to a region of the shuttle vector upstream of the insert cloning site but contains no adenoviral genomic sequence. The insert-specific primer (5`-GCTTCTTCCTGCGCATCC-3`) corresponds to codons 37-42 of the 18-kDa rat bFGF coding sequence. The recombinant virus was twice plaque-purified, and expression of the antisense transcript was confirmed by reverse transcription-PCR (RT-PCR). Total cellular RNA (1 µg) isolated from uninfected smooth muscle cells or cells infected with either Ad.ASbFGF or Ad5/RSV/GL2 was heat-denatured (65 °C for 5 min) and reverse-transcribed using 0.5 pmol of a sequence-specific primer. This primer contains 18 bases (5`-ACTTCGCTTCCCGCACTG-3`) of bFGF sequence complementary to the antisense strand (corresponding to codons 7-12 of 18-kDa rat bFGF) at the 3` end, as well as a 30-base random sequence at the 5` end (5`-CTTATACGGATATCCTGGCAATTCGGACTT-3`). The 5` end random sequence tag permits subsequent PCR amplification with a primer corresponding to this tag sequence only, thus rendering the overall amplification both strand- and RNA-specific(30) . The 5` primer used for the PCR amplification (5`-GCACACACTCCCTTGATGGACAC-3`) corresponds to codons 71-78 of 18-kDa rat bFGF. As controls, each of the cellular RNAs was also reverse-transcribed using random hexamer primers (1 pmol), and these cDNA products were subsequently amplified using primers (5`-primer: 5`-CCTGAAGGGTGGTGCAAAAG-3`; 3`-primer: 5`-CCATCCACAGTCTTCTGAGTG-3`) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Reverse transcription was performed in a final reaction volume of 20 µl using 20 units of avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim) according to the supplier's recommendations, and controls included ASbFGF and sense GAPDH RNA transcripts generated in vitro using cDNA templates and bacteriophage T7 RNA polymerase as well as a no-template negative control. The ASbFGF in vitro transcript yields a 246-base pair RT-PCR amplification product that is indistinguishable from that generated from the ASbFGF recombinant adenoviral transcript; the GAPDH cDNA used to generate the in vitro transcript contains a 106-base deletion relative to the native mRNA, which is flanked by the PCR primer sites and thus generates a smaller RT-PCR amplification product (132 base pairs versus 238 base pairs, respectively). Ten percent of each cDNA product was amplified using 1 pmol of each pair of relevant primers, with one primer in each reaction 5`-end-labeled using T4 polynucleotide kinase (New England Biolabs, Beverly, MA) and [-P]ATP (6000 Ci/mmol, Amersham Corp.). The PCR was performed in a 20-µl volume using 1 unit/reaction of Taq polymerase (Perkin-Elmer) in an Ericomp thermal cycler (San Diego, CA) for 25 cycles using 1-min steps. Denaturation was done at 94 °C, annealing at 60 °C, and extension at 72 °C. Products were separated on a 6% polyacrylamide, 7 M urea gel and detected by autoradiography using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

Cell Culture and Western Blotting for Basic FGF

Cultured rat aortic smooth muscle cells (gift of Dr. Gary Owens, University of Virginia) were cultured in DF12 (equal parts Dulbecco's modified Eagle's and Ham's F12 media) supplemented with 10% fetal bovine serum (FBS) and antibiotics. Subconfluent cells were infected with recombinant adenoviruses and 3 days later harvested with trypsin, homogenized, and partially purified by heparin-agarose affinity chromatography (Bio-Rad, Richmond, CA) essentially as described(31) . Lysates from equal numbers of cells were loaded onto the heparin affinity matrix, eluted by boiling in SDS-PAGE sample buffer, separated by electrophoresis in 15% SDS-polyacrylamide gels, and electrophoretically transferred to a polyvinylidene difluoride membrane (Immobilon P; Millipore Corp., Bedford, MA) in Tris-glycine buffer containing methanol and SDS. The three isoforms of rat bFGF (32) were determined by probing with a monoclonal anti-bovine bFGF antibody (Type II, Upstate Biotechnology, Lake Placid, NY) detected by enhanced chemiluminescence (ECL; Amersham Corp.) using a secondary anti-mouse antibody conjugated with peroxidase, as recommended by the manufacturer. Similar results were obtained by immunoblotting whole cell lysates without prior affinity enrichment, and reprobing these blots with an antibody directed against beta-actin demonstrated equivalent protein loading (data not shown). For the bFGF and epidermal growth factor (EGF) rescue experiments, 25 ng/ml recombinant human bFGF (Upstate Biotechnology) or 50 ng/ml human EGF (Upstate Biotechnology) was added directly to each well daily. Tissue culture reagents were from Life Technologies, Inc. unless otherwise specified. Electrophoresis and other chemicals were from Boehringer Mannheim, Sigma, or Fisher (Fairlawn, NJ).

Assessment of Apoptosis

For assessment of cellular and nuclear morphology, cells were grown on glass coverslips, infected with recombinant adenoviruses, and 48-72 h later fixed in 4% paraformaldehyde. Coverslips were imaged without staining under phase contrast optics or stained with 0.015% propidium iodide (Sigma) and imaged with epifluorescence illumination. The percentage of apoptotic cells was estimated by counting the numbers of apoptotic (condensed or fragmented) nuclei in at least 1000 cells imaged in contiguous fields on each coverslip, and the mean ± S.D. was calculated from determinations made on three independent coverslips. For 5-bromo-2`-deoxyuridine (BrdU) labeling, cells were pulse-labeled with 10 µM BrdU (Sigma) for 2 h prior to harvest, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma), and stained for BrdU using a fluorescein isothiocyanate-coupled monoclonal anti-BrdU antibody (Becton-Dickenson, San Jose, CA) according to the manufacturer's instructions. The BrdU-positive cells were imaged by epifluorescence microscopy, the percentage of positive cells was counted in at least 1000 cells in contiguous fields on each coverslip, and the mean ± S.D. was calculated from determinations made on three independent coverslips. For the detection of DNA strand breaks, cells were grown and infected on glass coverslips, fixed in 4% paraformaldehyde, labeled using the fluorescein-based ApopTag kit (Oncor, Gaithersburg, MD) according to the manufacturer's instructions, and imaged by epifluorescence microscopy. Photomicrographs were obtained using Kodak Ektachrome film (Rochester, NY) and either a Zeiss Optiphot or an Olympus AX-70 microscope at times 200-400 magnification using phase contrast optics or epifluorescence with appropriate filters. For the detection of oligonucleosomal fragmentation, cells were collected with trypsin and subjected to hypotonic lysis in buffer containing Triton X-100, and a low molecular weight DNA fraction was isolated as described(33) . The low molecular weight fraction from equal numbers of cells was separated by electrophoresis through agarose, stained with ethidium bromide, and visualized by transillumination with UV light using an Eagle Eye apparatus (Stratagene, La Jolla CA). Total cellular DNA isolated from v-myc-transformed rat embryo fibroblasts exposed to 10 Gy of -radiation (gift of E. Bernhard) was used as a positive control for oligonucleosomal fragmentation.

Cell Cycle Phase Determination and Tritiated Thymidine Labeling

For flow cytometric analysis of cell cycle phase distribution, cells were infected with recombinant adenoviruses and harvested with trypsin, and nuclei were prepared and stained with propidium iodide as described(34) . Flow cytometric analysis was performed using a FACScan cytometer (Becton-Dickenson, San Jose, CA) and analyzed using ModFitLT curve-fitting software (Verity Software, Topsham, ME) running on a Macintosh computer (Apple, Cupertino, CA). For tritiated thymidine labeling, sham- or adenovirus-infected cells were labeled 2 days following infection for 12 or 18 h in serum-free medium containing 1-2 µCi/ml [methyl-^3H]thymidine (Amersham Corp.), fixed in trichloroacetic acid, solubilized in dilute NaOH, and collected by filtration, and incorporation was determined by scintillation counting (Beckman Instruments, Columbia, MD).


RESULTS

Antisense Inhibition of Endogenous bFGF Triggers Smooth Muscle Cell Death

Expression of an antisense bFGF RNA (Fig. 1A) by a recombinant adenovirus (Ad.ASbFGF) in cultured smooth muscle cells markedly reduced cellular bFGF content (Fig. 1B). To test the hypothesis that inhibition of endogenous bFGF expression reduces either smooth muscle cell proliferation or survival, cell number was monitored following Ad.ASbFGF infection (Fig. 2). The expected accumulation of smooth muscle cells cultured in 10% FBS was inhibited by Ad.ASbFGF in a dose-dependent fashion (panel A) and could be prevented by exogenous bFGF (panel B). In order to distinguish between an inhibition of proliferation and promotion of cell death, quiescent smooth muscle cells were infected with the antisense bFGF virus and maintained in low (0.5%) serum. The number of antisense-infected cells decreased in a dose-dependent fashion (panel C), indicating cell death, which was subsequently identified as apoptosis by accepted morphologic and biochemical criteria.


Figure 1: Expression of an antisense bFGF RNA inhibits endogenous bFGF expression. Rat aortic smooth muscle cells were sham-infected or infected with either Ad.ASbFGF or Ad5/RSV/GL2 recombinant adenoviruses at a multiplicity of infection (MOI) of 1000. RT-PCR analysis (A) was performed on total RNA isolated from cells infected with either Ad.ASbFGF (lane 2, AS) or Ad5/RSV/GL2 (lane 3, Luc) and from uninfected cells (lane 4, Un). Controls included a synthetic ASbFGF transcript generated from a cDNA template in vitro (lane 5, +C) and no template (lane 1, -C). Each of the cellular RNAs was also analyzed for a control mRNA transcript, GAPDH, using a synthetic GAPDH transcript containing a short deletion (GAPDH) as a positive control. This experiment was repeated at least five times using independent RNA samples and alternative primer sets with similar results. Basic FGF cell content was determined by Western (immunoblot) analysis (B). Both uninfected cells (lane 1) and cells infected with Ad5/RSV/GL2 (lane 2) contain equivalent amounts of all three isoforms of rat bFGF, whereas Ad.ASbFGF-infected cells (lane 3) contain much less immunoreactive bFGF. This analysis was repeated three times with similar results.




Figure 2: Antisense inhibition of endogenous bFGF synthesis provokes cell death in either high or low serum, which can be prevented by exogenous bFGF. Antisense inhibition of bFGF expression reduces the accumulation of cells cultured in 10% FBS (A). Cells were infected with Ad.CMVlacZ at an MOI = 1000 (open squares), or Ad.ASbFGF at an MOI = 50 (filled diamonds), 100 (filled triangles), or 1000 (filled circles) and maintained in 10% FBS. Cells were counted daily starting on the day after infection; individual data points in this and each of the experiments in this figure represent the mean ± S.D. of triplicate wells, and each experiment was repeated at least three times. For the bFGF rescue experiment (B), cells were infected with Ad.CMVlacZ or Ad.ASbFGF at an MOI = 100; bFGF was added daily starting 1 day following infection, and cell counts were monitored. Cells infected with Ad.CMVlacZ and cultured in the absence (open squares), or presence (open circles) of bFGF were compared with cells infected with Ad.ASbFGF in the absence (filled squares) or presence (filled circles) of bFGF. To distinguish between inhibition of proliferation and promotion of cell death, cells were cultured in 0.5% serum to maintain quiescence both prior to and following infection with recombinant adenoviruses (C). Cells were infected with either Ad5/RSV/GL2 at an MOI = 1000 (open squares) or with Ad.ASbFGF at an MOI = 100 (filled triangles) or 1000 (filled circles), and cell counts were monitored daily.



Criteria for Apoptosis in Cells Infected with the Antisense bFGF Adenovirus

Cells infected with the antisense bFGF virus appeared normal for the first 24 h, but thereafter alterations in cellular and nuclear morphology and evidence of DNA fragmentation were observed (Fig. 3). Cells became rounded, developed vesiculations around the cell borders (panels A and B), and displayed condensation of nuclear chromatin, nuclear fragmentation (panels C and D), and evidence of DNA strand breaks (panels E-H). Agarose gel electrophoresis of the low molecular weight DNA (soluble cytoplasmic fraction) isolated from equal numbers of smooth muscle cells showed prominent oligonucleosomal fragmentation in Ad.ASbFGF-infected cells, which was barely detectable in control virus-infected cells and was undetectable in uninfected cells (Fig. 4). Nonspecific viral toxicity as a cause of cell death was excluded by the normal appearance of cells infected with similar doses of control viruses, in contrast to the rapid killing of cells (<12 h) intentionally infected at a very high multiplicities of infection, which was characterized by cell swelling and lysis. The delay of >24 h between infection with Ad.ASbFGF and the appearance of apoptosis suggests that cells are initially protected by existing bFGF protein and that the content of bFGF must fall below a critical level before apoptosis is initiated.


Figure 3: Antisense inhibition of bFGF expression induces apoptosis: morphologic and biochemical criteria. Cells infected at an MOI = 1000 with Ad.CMVlacZ (A and C) and Ad.ASbFGF (B and D) were photographed using either phase contrast or epifluorescence microscopy. Ad.CMVlacZ-infected cells showed normal cell morphology (A), whereas Ad.ASbFGF-infected cells displayed rounding and blebbing (B). Ad.CMVlacZ-infected cells (C) displayed normal nuclear morphology compared with condensation of nuclear chromatin and nuclear fragmentation in Ad.AsbFGF-infected cells (D). Cells stained using the TUNEL reaction (E-H) revealed positive staining in Ad.ASbFGF-infected cells (E). Negative controls included Ad.ASbFGF-infected cells incubated with reaction buffer lacking TdT (F), and both uninfected (G) and Ad5/RSV/GL2-infected cells (H) incubated with reaction buffer containing TdT.




Figure 4: Antisense inhibition of bFGF expression induces oligonucleosomal fragmentation. The low molecular weight DNA fraction prepared from equal numbers of sham-infected and Ad5/RSV/GL2- or Ad.ASbFGF-infected cells was displayed by agarose gel electrophoresis. Lane 1, 123-base pair markers; lane 2, uninfected cells; lane 3, Ad5/RSV/GL2-infected cells; lane 4, Ad.ASbFGF-infected cells; lane 5, positive control (v-myc-transformed rat embryo fibroblasts exposed to 10 Gy -radiation, total cellular DNA).



Apoptosis can be induced in some cell types by deprivation of specific growth factors(19, 20, 35, 36, 37) . Other cell types, including vascular smooth muscle cells(38) , survive well when cultured in serum-free medium but undergo apoptosis when forced into S phase in the absence of serum by constitutive expression of cell cycle transcription factors like c-myc(39, 40) or E2F(41, 42) . Apoptosis triggered by antisense inhibition of bFGF production might resemble a growth factor withdrawal model if it could be prevented by heterologous growth factor signaling pathways(43) . Alternatively, it might conform to the second type of apoptotic mechanism involving inappropriate S phase entry. To distinguish between these two possibilities, the ability of a different growth factor to prevent apoptosis following infection with Ad.ASbFGF was assessed, and the degree of S phase entry was estimated by flow cytometry, rates of DNA synthesis, and BrdU labeling of apoptotic nuclei in Ad.ASbFGF-infected cells.

Epidermal Growth Factor Does Not Prevent Apoptosis Triggered by Ad.ASbFGF

EGF, similar to exogenous bFGF, was able to prevent the reduction in the number of Ad.ASbFGF-infected cells over time in either high or low serum (data not shown). However, the ability of added growth factors to prevent the reduced accumulation of cells over time does not distinguish between the prevention of cell death and the stimulation of proliferation in the surviving cells. In order to make this distinction, the extent of apoptosis in the presence or absence of growth factors was assessed by the percentage of apoptotic nuclei visualized by propidium iodide staining. In cells cultured in 0.5% FBS in the absence of growth factors and infected at an MOI of 1000 with either Ad.ASbFGF or control virus, the percentage of apoptotic nuclei in control virus-infected cells was 0.5 ± 0.5% (mean ± S.D. of triplicate samples) compared with 18.9 ± 4.4% in Ad.ASbFGF-infected cells, which was also associated with a 20% decrease in cell number. In Ad.ASbFGF-infected cells treated with bFGF, the percentage of apoptotic nuclei was only 8 ± 1.1% compared with 15.5 ± 4.7% in cells treated with EGF, despite a similar (2-fold) increase in cell number stimulated by either growth factor in both control virus- or Ad.ASbFGF-infected cells. These data show that despite a similar stimulation of proliferation in non-apoptotic cells, bFGF but not EGF was able to reduce the proportion of apoptotic cells. This result suggests that apoptosis triggered by inhibition of autocrine bFGF synthesis does not correspond to a growth factor withdrawal model of apoptosis or that it involves signaling pathways that are not shared by bFGF and EGF. An alternative hypothesis, that apoptosis triggered by inhibition of autocrine bFGF synthesis involves disruption of normal cell cycle regulation, was tested by examining several complementary measures of cell cycle activity.

Apoptosis Induced by Ad.ASbFGF Involves Inappropriate S Phase Entry

Analysis of cell cycle activity in Ad.ASbFGF- versus control virus-infected smooth muscle cells suggested that an inappropriate entry into S phase participates in the mechanism of apoptosis due to inhibition of autocrine bFGF synthesis. By flow cytometric analysis, Ad.ASbFGF-infected cells displayed a marked increase in the proportion of cells in S phase at the expense of the G(0)/G(1) population (Fig. 5), and a time course experiment demonstrated an abrupt transition from a normal cell cycle phase distribution to one characterized by an increase in S phase between 16 and 20 h after infection (data not shown). These findings were confirmed by measuring rates of DNA synthesis by tritiated thymidine labeling (Fig. 6), which were greater in Ad.ASbFGF-infected versus control cells. The magnitude of the difference in thymidine labeling appeared to be dose-related (Fig. 6A), and at the higher MOI thymidine incorporation was about 2-fold the value in control cells. This result could be interpreted to mean that twice as many Ad.ASbFGF-infected cells were incorporating thymidine as control cells, an interpretation consistent with the flow cytometry results. This suggests that the excess DNA synthesis in the Ad.ASbFGF-infected cells was due to apoptosis, and this was made more apparent by thymidine labeling in quiescent cells (Fig. 6B). Under these circumstances, the thymidine incorporation in the control cells is very low, and the difference in labeling is apparently due to DNA synthesis in the proportion of cells undergoing apoptosis. This conclusion was supported by BrdU pulse labeling and immunofluorescence imaging of cells that had been infected with either Ad.ASbFGF or control viruses (Fig. 7), which showed that approximately 20% of cells were BrdU-labeled and that about half of these labeled cells had apoptotic (condensed or fragmented) nuclei, demonstrating that the increased DNA synthesis was associated with apoptosis and was not simply a compensatory response of the surviving cells. These data demonstrate that apoptosis induced by inhibition of bFGF synthesis involves an inappropriate entry into S phase, similar to other models of apoptosis involving disrupted cell cycle regulation, and suggests that autocrine FGF signaling participates in cell cycle regulation as part of its survival function.


Figure 5: Antisense inhibition of endogenous bFGF expression provokes inappropriate entry into S phase. Nuclei from SMCs infected with either Ad.ASbFGF (A), Ad5/RSV/GL2 (B), Ad.CMVlacZ (C), or uninfected cells (D) were prepared and analyzed for cell cycle distribution by flow cytometry as described in ``Experimental Procedures.'' Using curve-fitting software to estimate the cell cycle phase distributions, the estimated proportion of cells in S phase in each of the control samples (B, C, or D) ranged from 9-15%. In contrast, the estimated proportion of Ad.ASbFGF-infected cells in S phase was 53%.




Figure 6: Antisense inhibition of endogenous bFGF expression provokes inappropriate DNA synthesis in high or low serum. Rates of DNA synthesis were measured by thymidine incorporation in cells cultured in either 10% FBS (A) or 0.5% FBS (B). In panel A, cells were labeled for 18 h; in panel B, they were labeled for 12 h. The data, expressed as dpm/100 cells, represent the mean ± S.D. from triplicate wells normalized to cell number, determined by counting of companion wells.




Figure 7: Increased DNA synthesis is associated with apoptotic nuclei. Smooth muscle cells infected with either Ad.ASbFGF (A and C) or Ad5/RSV/GL2 (B and D) recombinant adenoviruses at an MOI of 1000 were pulse-labeled with BrdU for 2 h prior to fixation and staining with a fluorescent anti-BrdU antibody and counterstaining with propidium iodide. The fluorescein isothiocyanate-labeled anti-BrdU images (A and B) correspond to the same fields as the propidium iodide fluorescence images (C and D) and show that in addition to the greater proportion of labeled cells in the Ad.ASbFGF-infected sample, there is intense staining associated with nuclei displaying abnormal morphology, interpreted as indicating apoptosis.




DISCUSSION

This study demonstrates that inhibition of endogenous basic FGF synthesis using an antisense strategy triggers apoptosis in cultured vascular smooth muscle cells, supporting an essential survival function for autocrine FGF signaling in this cell type. Prior studies implicating fibroblast growth factors as survival factors in mesodermal and neuroectodermal cells (14, 16, 17, 19, 20, 31, 44) suggest that this survival function is related to prevention of apoptosis (19, 20, 44) but do not distinguish between mitogenic and survival-promoting activities.

Overexpression of FGF can lead to a transformed phenotype(45, 46, 47, 48, 49, 50) , supporting the idea that autocrine FGF signaling can drive proliferation, but interactions between FGFs and transmembrane FGF receptors may be required for FGF-stimulated mitogenesis(45, 46, 47, 48, 49) . On the other hand, selective overexpression of the high molecular weight isoforms of bFGF can either promote or inhibit proliferation without evidence of receptor interaction(50, 51) . None of these studies establish that autocrine FGF signaling is either necessary or sufficient for proliferation in cells capable of such autocrine loops. The mechanism of apoptosis in the present study appears to be independent of proliferation, as it occurs in cells cultured in either high (10%) or low (0.5%) serum. The ability of exogenous bFGF to prevent apoptosis may be related to activation of receptor-mediated signal transduction pathways or to internalization of ligand per se, although the inability of epidermal growth factor to block this mechanism of apoptosis suggests that receptor-mediated signaling may be less important. Thus the survival function of endogenous bFGF in smooth muscle cells appears to involve signal transduction pathways that may be distinct from those mediating mitogenesis. Experiments in transfected skeletal myoblasts (52) and fibroblasts (51) support important differences between FGF signaling pathways controlling mitogenesis and other cell functions.

The data presented establish that the pathway of apoptosis triggered by inhibition of autocrine FGF signaling involves an inappropriate entry into S phase. The possibility that DNA repair mechanisms contribute to the observed increase in total DNA synthesis has not been excluded, but the cell cycle phase analysis suggests that S phase entry is the predominant, if not exclusive, mechanism responsible. In this aspect it resembles other models of apoptosis that are due to disruption of normal cell cycle regulation. Unregulated expression of c-myc(39, 40) or E2F (41, 42) induces an inappropriate S phase entry and triggers apoptosis in the absence of serum. These pathways of apoptosis can be understood, at least in the case of E2F, by alteration in the regulatory balance between E2F and the retinoblastoma gene product, normally regulated by cyclins and cyclin-dependent kinase inhibitors. It is possible that expression of adenoviral genes in conjunction with the antisense bFGF transcript could be contributing to the observed phenotype. The adenoviral protein E1A interacts with cell cycle regulators such as the retinoblastoma protein and is a recognized inducer of apoptosis(22, 53) . Although the recombinant viruses used in this study are specifically E1-deleted, contamination with E1-expressing virus, although highly unlikely, has not been rigorously excluded. Although a direct relationship between FGF signaling and the activities of cell cycle regulatory proteins has not been demonstrated, the present study provides more direct evidence of the ability of autocrine FGF signaling to influence cell cycle regulation than has previously been reported.

Antisense inhibition of endogenous bFGF expression leads to an interruption of autocrine FGF signaling that appears to alter cell cycle regulation, resulting in apoptosis of vascular smooth muscle cells. These observations provide a mechanism that could explain the survival function of FGFs expressed in quiescent or terminally differentiated cells. The expression of FGFs is widely detectable in mesodermal and neuroectodermal lineages of adult organisms, and autocrine FGF signaling may well play a role in the cellular homeostasis and survival of these cell types. The present work provides insights into the autocrine functions of FGF and the signaling pathways whereby endogenous FGF prevents apoptosis are currently being explored.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grants HL02939 and HL26831 and grants from Bristol-Myers Squibb, The Margaret Q. Landenberger Research Foundation, and the Thomas B. and Jeannette E. Laws McCabe Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Medicine, University of Pennsylvania, 809c Stellar-Chance Laboratories, 422 Curie Blvd., Philadelphia, PA 19104-6069. Tel.: 215-662-2933; Fax: 215-573-2094; foxj{at}mail.med.upenn.edu.

(^1)
The abbreviations used are: bFGF, basic fibroblast growth factor; FGF, fibroblast growth factor; PCR, polymerase chain reaction; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FBS, fetal bovine serum.


ACKNOWLEDGEMENTS

We thank J. Swain for helpful discussions and critical reading of the manuscript; S. Kato for help with the ligand rescue experiments; E. Bernhard for advice and generous assistance with assays of apoptosis; G. Owens for cells; J. Wilson for Ad.CMVlacZ and assistance with construction of the ASbFGF adenoviral vector; B. French for the Ad5/RSV/GL2 vector; and A. Baird for the rat bFGF cDNA.


REFERENCES

  1. Gospodarowicz, D., Ferrara, N., Schweigerer, L., and Neufeld, G. (1987) Endocr. Rev. 8, 95-114 [Medline] [Order article via Infotrieve]
  2. Burgess, W. H., and Maciag, T. (1989) Annu. Rev. Biochem. 58, 575-606 [CrossRef][Medline] [Order article via Infotrieve]
  3. Gospodarowicz, D., Ferrara, N., Haaparanta, T., and Neufeld, G. (1988) Eur. J. Cell Biol. 46, 144-151 [Medline] [Order article via Infotrieve]
  4. Olson, N. E., Chao, S., Lindner, V., and Reidy, M. A. (1992) Am. J. Pathol. 140, 1017-1023 [Abstract]
  5. Lindner, V., and Reidy, M. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3739-3743 [Abstract]
  6. Sato, Y., Hamanaka, R., Ono, J., Kuwano, M., Rifkin, D. B., and Takaki, R. (1991) Biochem. Biophys. Res. Commun. 174, 1260-1266 [Medline] [Order article via Infotrieve]
  7. Becker, D., Meier, C. B., and Herlyn, M. (1989) EMBO J. 8, 3685-3691 [Abstract]
  8. Murphy, P. R., Sato, Y., and Knee, R. S. (1992) Mol. Endocrinol. 6, 877-884 [Abstract]
  9. Sugi, Y., Sasse, J., and Lough, J. (1993) Dev. Biol. 157, 28-37 [CrossRef][Medline] [Order article via Infotrieve]
  10. Ensoli, B., Markham, P., Kao, V., Barillari, G., Fiorelli, V., Gendelman, R., Raffeld, M., Zon, G., and Gallo, R. C. (1994) J. Clin. Invest. 94, 1736-1746 [Medline] [Order article via Infotrieve]
  11. Flaumenhaft, R., Moscatelli, D., Saksela, O., and Rifkin, D. B. (1989) J. Cell. Physiol. 140, 75-81 [Medline] [Order article via Infotrieve]
  12. Terrell, G. E., and Swain, J. L. (1991) Matrix 11, 108-114 [Medline] [Order article via Infotrieve]
  13. Vlodavsky, I., Fuks, Z., Ishai-Michaeli, R., Bashkin, P., Levi, E., Korner, G., Bar-Shavit, R., and Klagsbrun, M. (1991) J. Cell. Biochem. 45, 167-176 [Medline] [Order article via Infotrieve]
  14. Tamm, I., Kikuchi, T., and Zychlinsky, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3372-3376 [Abstract]
  15. Renaud, F., Oliver, L., Desset, S., Tassin, J., Romquin, N., Courtois, Y., and Laurent, M. (1994) J. Cell. Physiol. 158, 435-443 [Medline] [Order article via Infotrieve]
  16. Unsicker, K., Reichert-Preibsch, H., and Wewetzer, K. (1992) Brain Res. 65, 285-288
  17. Louis, J. C., Magal, E., Gerdes, W., and Seifert, W. (1993) Eur. J. Neurosci. 5, 1610-1621 [Medline] [Order article via Infotrieve]
  18. Blottner, D., and Baumgarten, H. G. (1992) Exp. Neurol. 118, 35-46 [Medline] [Order article via Infotrieve]
  19. Pittman, R. N., Wang, S., DiBenedetto, A. J., and Mills, J. C. (1993) J. Neurosci. 13, 3669-3680 [Abstract]
  20. Araki, S., Shimada, Y., Kaji, K., and Hayashi, H. (1990) Biochem. Biophys. Res. Commun. 168, 1194-1200 [Medline] [Order article via Infotrieve]
  21. Haimovitz-Friedman, A., Balaban, N., McLoughlin, M., Ehleiter, D., Michaeli, J., Vlodavsky, I., and Fuks, Z. (1994) Cancer Res. 54, 2591-2597 [Abstract]
  22. Bennett, M. R., Evan, G. I., and Schwartz, S. M. (1995) J. Clin. Invest. 95, 2266-2274 [Medline] [Order article via Infotrieve]
  23. Cho, A., Courtman, D. W., and Langille, B. L. (1995) Circ. Res. 76, 168-175 [Abstract/Free Full Text]
  24. Geng, Y. J., and Libby, P. (1995) Am. J. Pathol. 147, 251-266 [Abstract]
  25. Isner, J. M., Kearney, M., Bortman, S., and Passeri, J. (1995) Circulation 91, 2703-2711 [Abstract/Free Full Text]
  26. Shimasaki, S., Emoto, N., Koba, A., Mercado, M., Shibata, F., Cooksey, K., Baird, A., and Ling, N. (1988) Biochem. Biophys. Res. Commun. 157, 256-263 [Medline] [Order article via Infotrieve]
  27. Yang, Y., Raper, S. E., Cohn, J. A., Engelhardt, J. F., and Wilson, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4601-4605 [Abstract]
  28. Berkner, K. L. (1988) BioTechniques 6, 616-629 [Medline] [Order article via Infotrieve]
  29. French, B. A., Mazur, W., Ali, N. M., Geske, R. S., Finnigan, J. P., Rodgers, G. P., Roberts, R., and Raizner, A. E. (1994) Circulation 90, 2402-2413 [Abstract]
  30. Shuldiner, A. R., Perfetti, R., and Roth, J. (1993) in PCR Protocols: Current Methods and Applications (White, B. A., ed) pp. 169-176, Humana Press, Totowa, NJ
  31. Speir, E., Tanner, V., Gonzalez, A. M., Farris, J., Baird, A., and Casscells, W. (1992) Circ. Res. 71, 251-259 [Abstract]
  32. Brigstock, D. R., Klagsbrun, M., Sasse, J., Farber, P. A., and Iberg, N. (1990) Growth Factors 4, 45-52 [Medline] [Order article via Infotrieve]
  33. Yasuda, T., Grinspan, J., Stern, J., Franceschini, B., Bannerman, P., and Pleasure, D. (1995) J. Neurosci. Res. 40, 306-317 [Medline] [Order article via Infotrieve]
  34. Vindeløv, L. L., and Christensen, I. J. (1990) Cytometry 11, 753-770 [Medline] [Order article via Infotrieve]
  35. Rukenstein, A., Rydel, R. E., and Greene, L. A. (1991) J. Neurosci. 11, 2552-2563 [Abstract]
  36. Kinoshita, T., Yokota, T., Arai, K., and Miyajima, A. (1995) Oncogene 10, 2207-2212 [Medline] [Order article via Infotrieve]
  37. Wang, H. G., Millan, J. A., Cox, A. D., Der, C. J., Rapp, U. R., Beck, T., Zha, H., and Reed, J. C. (1995) J. Cell Biol. 129, 1103-1114 [Abstract]
  38. Libby, P., and O'Brien, K. V. (1983) J. Cell. Physiol. 115, 217-223 [Medline] [Order article via Infotrieve]
  39. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. (1992) Cell 69, 119-128 [Medline] [Order article via Infotrieve]
  40. Bennett, M. R., Evan, G. I., and Newby, A. C. (1994) Circ. Res. 74, 525-536 [Abstract]
  41. Qin, X. Q., Livingston, D. M., Kaelin, W. G., Jr., and Adams, P. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10918-10922 [Abstract/Free Full Text]
  42. Shan, B., and Lee, W. H. (1994) Mol. Cell. Biol. 14, 8166-8173 [Abstract]
  43. Yao, R. J., and Cooper, G. M. (1995) Science 267, 2003-2006 [Medline] [Order article via Infotrieve]
  44. Fuks, Z., Persaud, R. S., Alfieri, A., McLoughlin, M., Ehleiter, D., Schwartz, J. L., Seddon, A. P., Cordon-Cardo, C., and Haimovitz-Friedman, A. (1994) Cancer Res. 54, 2582-2590 [Abstract]
  45. Blam, S. B., Mitchell, R., Tischer, E., Rubin, J. S., Silva, M., Silver, S., Fiddes, J. C., Abraham, J. A., and Aaronson, S. A. (1988) Oncogene 3, 129-136 [Medline] [Order article via Infotrieve]
  46. Rogelj, S., Weinberg, R. A., Fanning, P., and Klagsbrun, M. (1988) Nature 331, 173-175 [CrossRef][Medline] [Order article via Infotrieve]
  47. Moscatelli, D., and Quarto, N. (1989) J. Cell Biol. 109, 2519-2527 [Abstract]
  48. Quarto, N., Talarico, D., Sommer, A., Florkiewicz, R., Basilico, C., and Rifkin, D. B. (1989) Oncogene Res. 5, 101-110 [Medline] [Order article via Infotrieve]
  49. Yayon, A., and Klagsbrun, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5346-5350 [Abstract]
  50. Quarto, N., Talarico, D., Florkiewicz, R., and Rifkin, D. B. (1991) Cell Regul. 2, 699-708 [Medline] [Order article via Infotrieve]
  51. Bikfalvi, A., Klein, S., Pintucci, G., Quarto, N., Mignatti, P., and Rifkin, D. B. (1995) J. Cell Biol. 129, 233-243 [Abstract]
  52. Fox, J. C., Hsu, A. Y., and Swain, J. L. (1994) Mol. Cell. Biol. 14, 4244-4250 [Abstract]
  53. Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., and White, E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7742-7746 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.